Application of animal bifidobacterium subsp. Lactis SF in preparation with malnutrition relieving function
By combining Bifidobacterium lactis subsp. SF with galactooligosaccharides, the problem of malnutrition in children was solved, and weight gain, gut health and GH-IGF axis expression were improved, thus achieving effective relief of malnutrition.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANCHANG UNIV
- Filing Date
- 2026-02-11
- Publication Date
- 2026-05-15
AI Technical Summary
Existing technologies are insufficient to effectively alleviate childhood malnutrition, especially malnutrition caused by low-fat and low-protein diets, which leads to reduced weight gain, intestinal damage, and decreased GH-IGF axis expression, thus affecting children's healthy development.
Using Bifidobacterium lactis subsp. SF and its metabolites or extracts, combined with galactooligosaccharides, drugs, health products or foods are prepared to improve malnutrition in children. By regulating intestinal flora and metabolism, enhancing GH-IGF axis expression, and promoting weight gain and intestinal health, these products can be used to improve malnutrition in children.
It significantly improved weight gain, intestinal damage, and GH-IGF axis expression in malnourished mice, regulated intestinal flora structure, enhanced bile acid biosynthesis, improved insulin sensitivity, and promoted healthy development in children.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically the field of microbiology, and specifically relates to a new application of Bifidobacterium lactis subspecies SF. Background Technology
[0002] Malnutrition is a clinical syndrome associated with deficiencies, excesses, or imbalances in energy and other macronutrients and micronutrients, including undernutrition (wasting, low weight, and stunting), vitamin or mineral deficiencies, and overnutrition (overweight and obesity). It is a leading cause of the global health burden. In 2022, 148.1 million (22.3%) children under five years of age suffered from stunting, 45 million (6.8%) from wasting, and 37 million (5.6%) from being overweight or obese. Nearly half of all deaths in children under five years of age are attributable to malnutrition. Chronic malnutrition can impair physical and cognitive development in children, reduce sensorimotor abilities and reproductive function, and increase susceptibility to infections and genetic diseases. Therefore, preventing and treating malnutrition is crucial to ensuring children's healthy growth and unlocking their full potential.
[0003] Probiotics are live, non-pathogenic microorganisms that can regulate the gut microbiota. Rational use of probiotics is beneficial to host health, including improving immune and neurological responses, epithelial resistance to pathogens, and maintaining intestinal barrier function. Probiotics are recommended supplements to restore metabolic stability in various forms of malnutrition. Bifidobacteria are well-known probiotics that promote gut health, and their probiotic effects include, but are not limited to, anti-infective, anti-cancer, anti-inflammatory, constipation relief, lactose intolerance improvement, mental health promotion, fat reduction, modulating the host immune system, promoting nutrient absorption, and promoting bone health. Prebiotics are nutrients selectively degraded by the gut microbiota, providing energy for gut microbiota survival and overall host health, and can be used as a treatment solution for childhood malnutrition. Intervention with a mixture of galactooligosaccharides and fructooligosaccharides increased the absorption of Ca, P, and Mg in protein-malnourished rats and improved bone development. Literature reports that galactooligosaccharide supplementation can improve blood parameters and health status in severely malnourished children, thereby reducing the risk of infection in infants.
[0004] In previous studies, we found that *Bifidobacterium animalis* subsp. *lactamase* SF exhibited high survival rates in simulated gastrointestinal transit and strong intestinal colonization capabilities, along with high extracellular polysaccharide production and excellent antioxidant capacity. Furthermore, *Bifidobacterium animalis* subsp. *lactamase* SF was able to inhibit the growth of colon cancer cell lines Caco-2 and HCT-8 in vitro. Additionally, *Bifidobacterium animalis* subsp. *lactamase* SF alleviated non-alcoholic fatty liver disease in mice by regulating gut microbiota and lipid metabolism. Therefore, *Bifidobacterium animalis* subsp. *lactamase* SF may be a potential probiotic that can improve host health and has application potential in alleviating malnutrition. Summary of the Invention
[0005] The purpose of this invention is to provide an application of Bifidobacterium lactis subsp. SF in the preparation of a formulation to alleviate malnutrition.
[0006] The first invention provides the application of Bifidobacterium animalis subsp. lactis SF as an active ingredient in the preparation of products to alleviate malnutrition, wherein the preservation number of Bifidobacterium animalis subsp. lactis SF is CCTCC NO: M 2021048.
[0007] Preferably, the malnutrition is caused by a low-fat, low-protein diet.
[0008] In some embodiments, the product also contains galactooligosaccharides.
[0009] In some embodiments, the Bifidobacterium animalis subsp. lactis SF exists as live bacterial cells or its metabolites, and / or its extracts.
[0010] In some embodiments, the product is a drug or probiotic preparation, or a health product or food. Any product can be used as long as *Bifidobacterium animalis* subsp. *lactobacter* SF can survive; the specific choice can be made according to actual needs.
[0011] The second invention provides a preparation for alleviating malnutrition, which is prepared from active ingredients including Bifidobacterium animalis subsp. lactis SF and galactooligosaccharides, wherein the preservation number of Bifidobacterium animalis subsp. lactis SF is CCTCC NO: M 2021048.
[0012] In some embodiments, the *Bifidobacterium animalis* subsp. *lactis* SF and galactooligosaccharides exist as two separate units or as a mixture. The *Bifidobacterium animalis* subsp. *lactis* SF and galactooligosaccharides are used in medically appropriate amounts according to the specific clinical needs of the user.
[0013] For example, in some embodiments, the dosage of Bifidobacterium in the formulation is 1 × 10⁻⁶. 8 cfu / mL -1×10 10 cfu / mL.
[0014] For example, the dosage of galactooligosaccharides is 0.5-3 g / kg / day.
[0015] In some embodiments, the active ingredients include Bifidobacterium animalis subsp. lactis SF, its metabolites, and / or extracts thereof.
[0016] In some embodiments, the preparation is a drug, health product, or food.
[0017] In some embodiments, the food product is a dairy product, vegetable product, beverage product, or other fermented product.
[0018] In some embodiments, the health product is a liquid health product, a granular health product, a powder health product, a capsule health product, or a tablet health product; or the medicine is a solution, granules, powder, capsule, or tablet.
[0019] The *Bifidobacterium animalis* SF described in this invention was deposited on January 12, 2021, at the China Center for Type Culture Collection (CCTCC M, address: No. 299 Bayi Road, Wuchang District, Wuhan, Hubei Province, 430072, China), with accession number CCTCC NO: M 2021048.
[0020] The beneficial effects of this invention are:
[0021] Our research revealed novel efficacy of *Bifidobacterium animalis* subspecies SF (CCTCC NO: M 2021048) in alleviating malnutrition, including reduced weight and body length growth and intestinal damage induced by low-fat, low-protein diets. Furthermore, *Bifidobacterium animalis* subspecies SF enhances GH-IGF axis expression, thereby promoting malnutrition relief. In addition, the combination of *Bifidobacterium animalis* subspecies SF with galactooligosaccharides enhances its malnutrition-improving effects and regulates intestinal metabolism, particularly enhancing bile acid biosynthesis. Therefore, *Bifidobacterium animalis* subspecies SF possesses significant potential medicinal value. Attached Figure Description
[0022] Figure 1 Example 1 uses animal experiments to model how Bifidobacterium lactis subsp. SF improves the reduced weight and length growth in malnourished mice; where a is the mouse weight gain, b is the mouse length gain, c is the mouse organ weight, d is the blood glucose change curve in the oral glucose tolerance test, e is the area under the blood glucose change curve, and f is the mouse serum insulin level.
[0023] Figure 2 The animal experiment results described in Example 2 show that intervention with Bifidobacterium lactis subsp. SF alone or in combination with galactooligosaccharides alleviated intestinal damage in malnourished mice; where a is the mouse colon H&E staining and AB-PAS staining, and bd is the quantitative map of mouse colon histological staining.
[0024] Figure 3 The animal experiment results described in Example 3 show that intervention with Bifidobacterium lactis subsp. SF alone or in combination with galactooligosaccharides enhances the expression of the GH-IGF axis in malnourished mice; where a is the serum growth hormone (GH) level, b is the serum insulin-like growth factor 1 (IGF-1) level, and c is the serum insulin-like growth factor 2 (IGF-2) level.
[0025] Figure 4 The animal experiment results described in Example 4 demonstrate that Bifidobacterium lactis subsp. SF, alone or in combination with galactooligosaccharides, regulates the gut microbiota of mice; where a is the principal coordinate analysis (PCoA) of the mouse gut microbiota, b is the species distribution at the phylum level of the mouse gut microbiota, and c is the species distribution at the genus level of the mouse gut microbiota.
[0026] Figure 5The animal experiment results described in Example 4 show that Bifidobacterium lactis subsp. SF combined with galactooligosaccharides altered the intestinal metabolome of malnourished mice; where a is the principal coordinate analysis (PCoA) of the mouse intestinal metabolome, b is the orthogonal partial least squares discriminant analysis (OPLS-DA) of the intestinal metabolome, c is the fold change analysis of metabolites between normal mice and malnourished mice, d is the overall change of metabolites enriched in the metabolic pathways of normal mice and malnourished mice, and e is the level of bile acids in the mouse intestine. Detailed Implementation
[0027] This invention provides the application of Bifidobacterium lactis subsp. SF in preparations for alleviating malnutrition.
[0028] The embodiments of the present invention will now be described in detail. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the present invention.
[0029] Unless otherwise specified, experimental methods in the following examples were performed under standard conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. All commonly used chemical reagents used in the examples were commercially available products.
[0030] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit the invention.
[0031] IGF-1: Insulin-like growth factor-1.
[0032] GH: Growth hormone.
[0033] The GH-IGF axis, short for growth hormone-insulin-like growth factor axis, is a core endocrine system in the human body that regulates growth, development, metabolism, and cell repair. It is a classic hypothalamic-pituitary-peripheral target organ (HPV) hormone axis. High levels of IGF-1 and GH in the blood negatively feedback-inhibit the hypothalamus (reducing GHRH and increasing SS) and the pituitary gland (reducing GH secretion), thereby maintaining the axis's balance. The core functions of the GH-IGF axis are promoting growth (childhood) and maintaining metabolism and body composition (lifelong).
[0034] The *Bifidobacterium animalis* SF described in this invention was deposited on January 12, 2021, at the China Center for Type Culture Collection (CCTCC M, address: No. 299 Bayi Road, Wuchang District, Wuhan, Hubei Province, 430072, China), with accession number CCTCC NO: M 2021048.
[0035] Example 1: Bifidobacterium animalis subsp. lactis SF improved reduced weight gain and insulin sensitivity in malnourished mice.
[0036] The lyophilized Bifidobacterium animalis subsp. lactis SF (CCTCC NO: M 2021048), frozen at -80℃, was picked up with an inoculation loop and streaked onto a sterile BS solid plate for activation. After anaerobic incubation at 37℃ for 24 h, it was revived. After two passages for activation, it was transferred to sterile BS liquid medium and incubated overnight. The activated Bifidobacterium animalis subsp. lactis SF was inoculated at 2% in sterile BS liquid medium and anaerobic incubated at 37℃ for 24 h. Viable cell counts were then performed. The culture was centrifuged at 8000 rpm for 3 min, and the supernatant was discarded. Based on the viable cell count, the cells were prepared into 1×10⁻⁶ cells using sterile 1×PBS buffer. 9 A bacterial culture of CFU / mL was prepared daily for the following experiments.
[0037] After one week of acclimatization, 50 three-week-old specific pathogen-free (SPF) male C57BL / 6 mice were randomly divided into a normal group (ND group), a model group (MD group), a probiotic group (SF group), a prebiotic group (GOS group), and a synbiotic group (GOSF group).
[0038] ND group: 24 days after the end of the adaptation period, mice were given a normal diet and sterile water, and were given 100 μL of sterile 1 × PBS buffer solution by gavage once a day.
[0039] MD group: They were given a low-fat, low-protein diet and sterile water, and were given 100 μL of sterile 1 × PBS buffer solution by gavage once a day for 24 days.
[0040] SF group: Received a low-fat, low-protein diet and sterile water, and were given 100 μL of 1×10 [unclear] via gavage once daily. 9 CFU / mL bacterial suspension, for 24 days;
[0041] GOS group: They were given a low-fat, low-protein diet and sterile drinking water supplemented with 1.5 g / kg / d of galactooligosaccharides, and were given 100 μL of sterile 1 × PBS buffer solution by gavage once a day for 24 days.
[0042] GOSF: Patients were given a low-fat, low-protein diet and sterile drinking water supplemented with 1.5 g / kg / day of galactooligosaccharides, administered via gavage once daily at a dose of 100 μL (1×10). 9 The bacterial culture was prepared at cfu / mL and continued for 24 days.
[0043] One week before the end of the experiment, the mice were fasted overnight and then force-fed 2.0 g / kg of glucose orally. Blood samples were taken from the tail at 0, 15, 30, 60, 90 and 120 min to detect glucose content.
[0044] Mice were weighed and measured every two days. After 24 days of intervention, blood was collected from the mice by enucleation and serum was stored at -80℃. After euthanizing the mice by cervical dislocation, organs such as the heart and liver were isolated and weighed. Serum insulin levels in mice were measured using an enzyme-linked immunosorbent assay (ELISA) kit.
[0045] Experimental results are as follows Figure 1 As shown, *Bifidobacterium animalis* subsp. *Lactobacillus* SF (SF group) significantly improved the reduced body length growth and liver weight loss in mice induced by a low-fat, low-protein diet. However, its combined intervention with galactooligosaccharides (GOSF group) also showed an ameliorative effect on the reduced body weight growth in mice. Figure 1 The mice in different groups had similar blood glucose levels (ac). Figure 1 (d, e), but the serum insulin level in the GOSF group was significantly lower than that in the MD and SF groups ( Figure 1 (f) This indicates that Bifidobacterium lactis subsp. SF combined with galactooligosaccharides significantly improved insulin sensitivity in mice.
[0046] Example 2: Bifidobacterium animalis subsp. lactis SF alleviated intestinal damage in malnourished mice.
[0047] The experimental procedure was the same as in Example 1. Twenty-four days after intervention, mice were euthanized by cervical dislocation, and the colon was isolated, flash-frozen in liquid nitrogen, and then stored at -80°C. H&E staining and AB-PAS staining were used to examine the pathological condition of the mouse colon tissue.
[0048] Experimental results are as follows Figure 2 As shown. According to H&E staining results, malnutrition in the MD group mice led to severe damage to the colonic mucosa, with significant loss of crypts and extensive inflammatory cell infiltration. Figure 2 (a). Furthermore, the histological score of the MD group was significantly higher than that of other groups, while the number of goblet cells was significantly lower in the MD group (a). Figure 2 (b, c). However, intervention with *Bifidobacterium animalis* subsp. *lactospirum* SF and / or galactooligosaccharides significantly alleviated the above symptoms. Figure 2According to AB-PAS staining results, the colonic mucus area in the MD group was lower than that in the ND group (p = 0.0982), while the colonic mucus area in the SF and GOSF groups was significantly higher than that in the MD group (p = 0.0982). Figure 3 (a, d). In summary, Bifidobacterium animalis subsp. lactis SF and / or galactooligosaccharides jointly alleviated intestinal damage in malnourished mice.
[0049] Example 3: Bifidobacterium animalis subsp. lactis SF enhanced GH-IGF axis expression in malnourished mice.
[0050] Animal modeling was performed in the same manner as in Example 1. Twenty-four days after intervention, blood was collected from the mice by enucleation, and serum was stored at -80°C. Serum levels of GH, IGF-1, and IGF-2 were measured using an enzyme-linked immunosorbent assay (ELISA) kit.
[0051] Experimental results are as follows Figure 3 As shown, serum GH, IGF-1, and IGF-2 levels in malnourished model mice were significantly lower than in normal mice; while in mice treated with Bifidobacterium lactis subsp. SF alone, serum IGF-1 and IGF-2 levels were significantly upregulated compared to the model mice; and in the GOSF group, serum GH was significantly upregulated compared to the model group, and the upregulation of IGF-1 and IGF-2 levels was even stronger than in the SF group. Figure 3 (ac). This indicates that *Bifidobacterium animalis* subsp. *Lactobacillus* SF enhanced the expression of the GH-IGF axis in malnourished mice, and galactooligosaccharides could enhance this effect.
[0052] Example 4: Bifidobacterium animalis subsp. lactis SF, alone or in combination with galactooligosaccharides, promotes intestinal health in malnourished mice.
[0053] 4.1 Animal experimental modeling was the same as in Example 1. After 24 days of intervention, mice were euthanized by cervical dislocation, and the contents of the cecum were isolated into sterile centrifuge tubes, flash-frozen in liquid nitrogen, and then stored at -80°C.
[0054] Genomic DNA was extracted from cecal contents using a fecal genomic DNA extraction kit and subjected to high-throughput sequencing. The V3-V4 region of the 16S rRNA gene was amplified from the genomic DNA of each sample using universal primers 338F: 5'-ACTCCTACGGGAGGCAGCA-3' (SEQ ID NO: 1) and 806R: 5'-GGACTACHVGGGTWTCTAAT-3' (SEQ ID NO: 2). These PCR products were sequenced on the Illumina NovaSeq platform of Biomarker Technologies. Valid data from all samples were clustered and output as ASVs, which were then annotated with a 70% confidence threshold. Beta diversity analysis utilized the phylogenetic relationships between ASVs, calculated the Unifrac distance, and performed principal coordinate analysis (PCoA) to identify differences between different samples (groups).
[0055] Experimental results are as follows Figure 4 As shown in the figure. PCoA analysis results showed that there was a significant separation in the gut microbiota structure of the five groups ( Figure 4 (a) Compared with the ND group, the abundance of Firmicutes decreased in the MD group, while the abundance of Actinobacteria increased, and these changes were partially reversed in both intervention groups. Figure 4 (b) In the SF, GOS, and GOSF groups, the relative abundance of Bacteroidetes and Dethiobacterium was higher than that in the MD group. Figure 4 (b). At the genus level, compared with other groups, *Faecalibaculum* was significantly enriched in the ND group, *Coriobacteriaceae_UCG_002* was significantly enriched in the MD group, *Ileibacterium* was significantly enriched in the SF group, and *Parabacteroides* was significantly enriched in the GOSF group. Figure 4 c) Decreased abundance of Faecalibacterium can lead to intestinal inflammation and incomplete intestinal epithelium, impairing intestinal barrier function, hindering intestinal development, and harming intestinal health. Coriobacteriaceae_UCG_002 belongs to the phylum Actinobacteria and is a harmful bacterium associated with abnormal metabolism and inflammation. Parabacteroides is a potential SCFA-producing bacterium closely related to human health and can enhance the body's nutrient uptake. Ileibacterium is a beneficial bacterium found in the gut, positively correlated with butyrate production, and may be related to the improvement of intestinal barrier structure. In summary, intervention with Bifidobacterium animalis subsp. lactis SF, independently or in combination with galactooligosaccharides, can regulate the intestinal flora structure in mice, reduce the abundance of harmful bacteria, increase the abundance of beneficial bacteria, and thus improve intestinal health.
[0056] 4.2 Animal experimental modeling was the same as in Example 1. After 24 days of intervention, mice in each group were sacrificed by cervical dislocation, and the contents of the cecum in each group were isolated into sterile centrifuge tubes, flash-frozen in liquid nitrogen, and then transferred to -80°C for storage.
[0057] Metabolites in the cecal contents of each experimental group were comprehensively analyzed using an LC / MS system. Raw data were processed using the original generation QI software. Identification was performed based on public databases and a database built by Biomarker Technologies. The raw peak area information was normalized to the total peak area before subsequent analysis. Metabolites were annotated using the KEGG, HMDB, and lipid pathway databases. Fold change (FC) was calculated and compared according to grouping, and p-values were determined using t-tests. Orthogonal projection discriminant analysis of potential structures (OPLS-DA) was modeled, and its reliability was verified using permutation tests. VIP values of metabolites were determined through multiple cross-validations. Differential metabolites were screened based on FC > 1, p < 0.05, and VIP > 1.
[0058] Experimental results are as follows Figure 5 As shown. PCoA and OPLS-DA analyses revealed significant differences in the intestinal metabolic profiles between the MD and GOSF groups of mice. Figure 5 (a, b). After intervention with Bifidobacterium animalis subsp. lactis SF combined with galactooligosaccharides (GOSF group), PA (22:4(7Z,10Z,13Z,16Z) / 16:0), Arachidonyl-CoA, and PE (20:3(6,8,11)-OH(5) / 16:0) in the intestines of malnourished mice were significantly upregulated. Figure 5 (c). Arachidonyl-CoA can serve as a substrate for lysophosphatidylcholine acyltransferase (LPCAT) and become a source of arachidonic acid in PCs. A decrease in the concentration of arachidonic acid-containing PCs in intestinal cells impairs the absorption of fatty acids in the intestine, thereby reducing food intake. mTORC1 is a major growth regulator during the period of most rapid growth in children, and PA can mediate mTORC1 signaling, which is crucial for mTORC1 activity. PE provides mechanical protection for intestinal epithelial cells and substantia nigra, which is essential for the growth and development of newborns. Studies have also shown that PE can regulate mucus secretion from intestinal goblet cells to improve growth retardation. According to KEGG annotation results, after intervention with Bifidobacterium animalis subsp. lactis SF combined with galactooligosaccharides, secondary bile acid biosynthesis was upregulated and taurine and hypotaurine metabolism was downregulated in malnourished mice. Figure 5(d). Regarding bile acids detected in cecal contents, we found that intervention with Bifidobacterium animalis subsp. lactis SF combined with galactooligosaccharides significantly increased the levels of cholic acid (CA), allocholic acid (ACA), and deoxycholic acid (DCA) in malnourished mice. Figure 5 (e). When primary bile acids bind with glycine or taurine into the small intestine, their emulsifying properties promote the absorption of dietary fats and fat-soluble vitamins. Microbial-derived secondary bile acids act as terminal electron acceptors in energy production, contributing to the formation of a hydrophobic pool of bile acids with less membrane damage and reducing the toxicity of intestinal pathogens. Furthermore, secondary bile acids can bind to intestinal receptors (such as FXR, TGR5, and MLCK), enhancing tight junction protein expression and shaping epithelial barrier function. These results indicate that combined intervention with *Bifidobacterium animalis* subsp. *liquid* SF and galactooligosaccharides alters intestinal metabolism in malnourished mice, enhancing bile acid biosynthesis, which may thus promote the growth and development of malnourished mice.
[0059] The above are merely specific embodiments of the present invention and are not intended to limit the scope of protection of the present invention; any substitutions and improvements made without departing from the concept of the present invention shall fall within the scope of protection of the present invention.
Claims
1. The application of Bifidobacterium animalis subsp. lactis SF as an active ingredient in the preparation of products to alleviate malnutrition, wherein the preservation number of Bifidobacterium animalis subsp. lactis SF is CCTCC NO: M 2021048.
2. The application according to claim 1, characterized in that, The product also contains galactooligosaccharides.
3. The application according to claim 1 or 2, characterized in that, The animal Bifidobacterium lactis subsp. SF exists in the form of live bacterial cells, its metabolites, and / or its extracts.
4. The application according to claim 1, characterized in that, The product is a drug or probiotic agent, or a health product or food.
5. A preparation for alleviating malnutrition, characterized in that, It is prepared from active ingredients including Bifidobacterium animalis subsp. lactis SF and galactooligosaccharides, wherein the preservation number of Bifidobacterium animalis subsp. lactis SF is CCTCC NO: M 2021048.
6. The malnutrition-relieving preparation according to claim 5, characterized in that, The Bifidobacterium animalis subsp. lactis SF and galactooligosaccharides exist as two separate units or as a mixture.
7. The malnutrition-relieving preparation according to claim 5, characterized in that, The animal Bifidobacterium lactis subsp. SF exists in the form of live bacterial cells, its metabolites, and / or its extracts.
8. The malnutrition-relieving preparation according to claim 5, characterized in that, The preparation is a drug, health product, or food.
9. The malnutrition-relieving preparation according to claim 8, characterized in that, The food products mentioned are dairy products, vegetable products, beverage products, and other fermented products.
10. The malnutrition-relieving preparation according to claim 8, characterized in that, The health products are in liquid, granular, powdered, capsule, or tablet form; or the medicines are in solution, granules, powder, capsule, or tablet form.